Astellas Pharma US | Changing Tomorrow | Home

Previous Pause Next

revised newest covid

UPDATES AND INFORMATION

Find out how we're responding to our patients, our employees and our community

alt text

Astellas Pharma Support Solutions Helps to Address Evolving Patient Needs During COVID-19 Read More

1

2

News

Latest

News / Media

Jun 05, 2020

Astellas, City of Yokohama, and Yokohama City University Developed Science-Based Exercise Programs through Industry-Government-Academia Collaboration

News / Media

May 20, 2020

Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme

News / IR

May 14, 2020

Posted Financial Results for FY2019

News / Therapeutic Area News

Jun 08, 2020

Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease

News / Therapeutic Area News

May 29, 2020

Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer

News / Therapeutic Area News

May 29, 2020

XTANDI® (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis